First-line medication dosing in pediatric refractory status epilepticus
Alejandra Vasquez,Marina Gaínza-Lein,Nicholas S Abend,Marta Amengual-Gual,Anne Anderson,Ravindra Arya,J Nicholas Brenton,Jessica L Carpenter,Kevin Chapman,Justice Clark,Raquel Farias-Moeller,William D Gaillard,Tracy Glauser,Joshua L Goldstein,Howard P Goodkin,Rejean M Guerriero,Kush Kapur,Yi-Chen Lai,Tiffani L McDonough,Mohamad A Mikati,Lindsey A Morgan,Edward J Novotny,Adam P Ostendorf,Eric T Payne,Katrina Peariso,Juan Piantino,James J Riviello,Kumar Sannagowdara,Robert C Tasker,Dmitry Tchapyjnikov,Alexis Topjian,Mark S Wainwright,Angus Wilfong,Korwyn Williams,Tobias Loddenkemper,Pediatric Status Epilepticus Research Group (pSERG),Seema Bansal,Sarah Kelley,Carl Stafstrom,Eric Kossoff,Christa Habela,Dalila Lewis,Tony Stanfield,Claudine Sculier,Cristina Barcia Aguilar,Arnold Sansevere,Melissa Sacco,Abby Duncan,Jordan McCoy,Kathryn DaSilva-Chiodo,Robert Faist,Daniel Santel,Victor LaFay,Peggy Clark,Sarah Borror,Andrea Debs,Caitlin Clohessy,Amanda Weber,Asri Yuliati,Aimee Luat,Azara Singh,Ashley Helseth,David Turner,Cecilia Fernandes,Linh Tran,Melissa McLean,Anuranjita Nayak,James J Riviello Jr,Kurt Hecox,Rupa Nallamothu,Rebecca Rehborg,David Goldstein,Erin Heinzen Cox,Colin Malone,Olivia Thornburg,Zachary Grinspan,Natasha Basma,Brian Appavu,Brian Burrows,Beata Dyar,Laura Mishler,Jacqueline Lee-Eng,Madison Streb,Cecil Hahn,Saptharishi Rishi Lalgudi Ganesan,Linda Huh,Nela Martic
DOI: https://doi.org/10.1212/WNL.0000000000010828
IF: 9.9
2020-11-10
Neurology
Abstract:Objective: To identify factors associated with low benzodiazepine (BZD) dosing in patients with refractory status epilepticus (RSE) and to assess the impact of BZD treatment variability on seizure cessation. Methods: This was a retrospective study with prospectively collected data of children with convulsive RSE admitted between June 2011 and January 2019. We analyzed the initial and total BZD dose within 10 minutes of treatment initiation. We used logistic regression modeling to evaluate predictors of low BZD dosing and multivariate Cox regression analysis to assess the impact of low BZD dosing on time to seizure cessation. Results: We included 289 patients (55.7% male) with a median age of 4.3 (1.3-9.5) years. BZDs were the initial medication in 278 (96.2%). Of those, 161 patients (57.9%) received a low initial dose. Low initial BZD doses occurred in both out-of-hospital (57 of 106; 53.8%) and in-hospital (104 of 172; 60.5%) settings. One hundred three patients (37.1%) received low total BZD dose. Male sex (odds ratio [OR] 2, 95% confidence interval [CI] 1.18-3.49; p = 0.012), older age (OR 1.1, 95% CI 1.05-1.17; p < 0.001), no prior diagnosis of epilepsy (OR 2.1, 95% CI 1.23-3.69; p = 0.008), and delayed BZD treatment (OR 2.2, 95% CI 1.24-3.94; p = 0.007) were associated with low total BZD dose. Patients who received low total BZD dosing were less likely to achieve seizure cessation (hazard ratio 0.7, 95% CI 0.57-0.95). Conclusion: BZD doses were lower than recommended in both out-of-hospital and in-hospital settings. Factors associated with low total BZD dose included male sex, older age, no prior epilepsy diagnosis, and delayed BZD treatment. Low total BZD dosing was associated with decreased likelihood of Seizure cessation. Classification of evidence: This study provides Class III evidence that patients with RSE who present with male sex, older age, no prior diagnosis of epilepsy, and delayed BZD treatment are more likely to receive low total BZD doses. This study provides Class III evidence that in pediatric RSE low total BZD dose decreases the likelihood of seizure cessation.